LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the formation of its Strategic Advisory Board and the appointment of its ...

Merck (MRK) stock in focus as anti-cancer agent Welireg is approved in the EU for kidney tumor conditions, VHL disease and ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

A transaction for SpringWorks would rank as one of the biggest pharma deals for Merck in recent years and boost its efforts to build out its cancer treatment pipeline. Merck has suffered high ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...

Merck (MRK.N), opens new tab and Japan-based Eisai (4523.T), opens new tab said on Friday a combination of their therapies failed to extend the lives of patients with a type of esophageal cancer ...

Merck Foundation marks World Cancer Day with African First Ladies by providing 194 scholarships of Oncology Training to African doctors from 32 countries. Merck Foundation together with Africa First ...

The company's diverse portfolio spans multiple therapeutic areas, with a particularly strong presence in oncology, vaccines, and infectious diseases. Merck's financial performance has remained ...

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks ...

In a rare win, the combo showed it could work on top of chemoembolization in intermediate-stage liver cancer. The repeated failures have prompted some criticism of Merck’s aggressive clinical ...